About Women’s Health
Women experience physiological and emotional issues during different phases of their life cycle due to hormonal changes. Women's health is especially referred to where reproductive health is involved. According to the Society for Women's Health Research in the US, issues specific to the human female anatomy are defined as women's health. The biological mechanisms influence the clinical course of diseases and disorders differently in women when compared to men. Some of the main women's health disorders include infertility, menopause, endometriosis and polycystic ovarian syndrome as well as urological disorders and cancers such as breast cancer, cervical cancer, endometrial cancer, and ovarian cancer. In addition, contraception plays an important role in women’s health for many reasons, so this too is also categorized under women's health.
TechNavio's analysts forecast the Global Women's Health market will grow at a CAGR of 3.52 percent over the period 2013-2018.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Women's Health market for the period 2014-2018. To calculate the market size, the report considers revenue generated from the sales of various products used for the wellbeing of women, which are listed below based on their application segment:
• Postmenopausal Osteoporosis (Drugs)
• Hormonal Contraceptives (Drugs and Devices)
• Menopause (Drugs)
• Infertility (Drugs)
• Endometriosis (Drugs)
• Polycystic Ovary Syndrome (Drugs)
TechNavio's report, the Global Women's Health Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, the EMEA, and the APAC regions; it also covers the Global Women's Health market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• EMEA
• APAC
Key Vendors
• Actavis plc
• Bayer AG
• Eli Lilly and Co.
• Merck & Co.
• Pfizer Inc.
Other Prominent Vendors
• AbbVie Inc.
• Adamis Pharmaceuticals Corp.
• Agile Therapeutics Inc.
• Amgen Inc.
• ANI Pharmaceuticals Inc.
• Apothecus Pharmaceutical Corp.
• AstraZeneca plc
• Blairex Laboratories Inc.
• Catalysis SL
• Crinetics Pharmaceuticals Inc.
• Dexa Medica Group
• EffRx Inc.
• Ferring International Center SA
• GlaxoSmithKline plc
• HLL Lifecare Ltd.
• Janssen Pharmaceutical Inc.
• Ligand Pharmaceuticals Inc.
• Lipocine Inc.
• Lupin Pharmaceuticals Inc.
• Mayer Laboratories
• Medicines 360
• Mylan Laboratories Inc.
• Neurocrine Biosciences Inc.
• Pantarhei Bioscience BV
• Teva Pharmaceuticals Inc.
Key Market Driver
• Increase in Aging Female Population
• For a full, detailed list, view our report.
Key Market Challenge
• Patent Expiry of Major Blockbuster Drugs
• For a full, detailed list, view our report.
Key Market Trend
• Rise in Strategic Partnerships
• For a full, detailed list, view our report.
Key Questions Answered in this Report
• What will the market size be in 2018 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
You can request one free hour of our analyst’s time when you purchase this market report. Details are provided within the report.
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Application
07.1.1 Postmenopausal Osteoporosis
07.1.2 Hormonal Contraceptives
07.1.3 Menopause
07.1.4 Infertility
07.1.5 Endometriosis
07.1.6 Polycystic Ovary Syndrome
08. Global Postmenopausal Osteoporosis Market
08.1 Market Overview
08.2 Market Size and Forecast
09. Global Hormonal Contraceptives Market
09.1 Market Overview
09.2 Market Size and Forecast
10. Global Menopause Market
10.1 Market Overview
10.2 Market Size and Forecast
11. Global Infertility Market
11.1 Market Overview
11.2 Market Size and Forecast
12. Global Endometriosis Market
12.1 Market Overview
12.2 Market Size and Forecast
13. Global Polycystic Ovary Syndrome Market
13.1 Market Overview
13.2 Market Size and Forecast
14. Geographical Segmentation
15. Buying Criteria
16. Market Growth Drivers
17. Drivers and their Impact
18. Market Challenges
19. Impact of Drivers and Challenges
20. Market Trends
21. Trends and their Impact
22. Vendor Landscape
22.1 Competitive Scenario
22.1.1 Key News
22.1.2 Mergers and Acquisitions
22.2 Market Share Analysis 2013
22.2.1 Sales of Major Women's Health Products 2013
22.3 Other Prominent Vendors
23. Key Vendor Analysis
23.1 Actavis plc
23.1.1 Key Facts
23.1.2 Business Description
23.1.3 Business Segmentation
23.1.4 Business Segmentation by Revenue 2012 and 2013
23.1.5 Sales by Geography
23.1.6 Business Strategy
23.1.7 Key Information
23.1.8 SWOT Analysis
23.1.9 Strengths
23.1.10 Weaknesses
23.1.11 Opportunities
23.1.12 Threats
23.2 Bayer AG
23.2.1 Key Facts
23.2.2 Business Overview
23.2.3 Business Segmentation
23.2.4 Business Segmentation by Revenue 2012 and 2013
23.2.5 Sales by Geography
23.2.6 Business Strategy
23.2.7 Key Information
23.2.8 SWOT Analysis
23.2.9 Strengths
23.2.10 Weaknesses
23.2.11 Opportunities
23.2.12 Threats
23.3 Eli Lilly and Co.
23.3.1 Key Facts
23.3.2 Business Overview
23.3.3 Business Segmentation by Revenue 2013
23.3.4 Business Segmentation by Revenue 2012 and 2013
23.3.5 Sales by Geography
23.3.6 Business Strategy
23.3.7 Key Developments
23.3.8 SWOT Analysis
23.3.9 Strengths
23.3.10 Weaknesses
23.3.11 Opportunities
23.3.12 Threats
23.4 Merck & Co. Inc.
23.4.1 Key Facts
23.4.2 Business Overview
23.4.3 Business Segmentation by Revenue 2013
23.4.4 Business Segmentation by Revenue 2012 and 2013
23.4.5 Sales by Geography
23.4.6 Business Strategy
23.4.7 Key Developments
23.4.8 SWOT Analysis
23.4.9 Strengths
23.4.10 Weaknesses
23.4.11 Opportunities
23.4.12 Threats
23.5 Pfizer Inc.
23.5.1 Key Facts
23.5.2 Business Overview
23.5.3 Business Segmentation by Revenue 2013
23.5.4 Business Segmentation by Revenue 2012 and 2013
23.5.5 Sales by Geography
23.5.6 Business Strategy
23.5.7 Key Developments
23.5.8 SWOT Analysis
23.5.9 Strengths
23.5.10 Weaknesses
23.5.11 Opportunities
23.5.12 Threats
24. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Women's Health Market 2013-2018 (US$ million)
Exhibit 3: List of Products for Women's Health Served by Other Prominent Players
Exhibit 4: Global Women's Health Market Segmentation by Application
Exhibit 5: Global Women's Health Market Segmentation by Application 2013
Exhibit 6: Global Women's Health Market Segmentation by Application 2013-2018 (in percent)
Exhibit 7: Global Women's Health Market Segmentation by Application 2013-2018 (US$ million)
Exhibit 8: Global Postmenopausal Osteoporosis Market 2013-2018 (US$ million)
Exhibit 9: Global Hormonal Contraceptives Market 2013-2018 (US$ million)
Exhibit 10: Global Menopause Market 2013-2018 (US$ million)
Exhibit 11: Global Infertility Market 2013-2018 (US$ million)
Exhibit 12: Global Endometriosis Market 2013-2018 (US$ million)
Exhibit 13: Global Polycystic Ovary Syndrome Market 2013-2018 (US$ million)
Exhibit 14: Global Women's Health Market by Geographical Segmentation
Exhibit 15: Global Women's Health market Business Segmentation 2013
Exhibit 16: Global Women's Health market Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 17: Actavis Plc: Sales by Geography (in US$ million)
Exhibit 18: Bayer AG: Business Segmentation 2013
Exhibit 19: Bayer AG: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 20: Bayer AG: Sales by Geography 2013
Exhibit 21: Eli Lilly and Co.: Business Segmentation by Revenue 2013
Exhibit 22: Eli Lilly and Co.: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 23: Eli Lilly and Co.: Sales by Geography 2013
Exhibit 24: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 25: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 26: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 27: Pfizer Inc.: Business Segmentation by Revenue 2013
Exhibit 28: Pfizer Inc.: Business Segmentation by Revenue 2012 and 2013
Exhibit 29: Pfizer Inc.: Sales by Geography 2013
